NO302884B1 - Krystallinske 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter, fremgangsmåte for fremstilling av de krystallinske karboksylatene, farmasöytiske preparater inneholdende disse og deres anvendelse - Google Patents

Krystallinske 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter, fremgangsmåte for fremstilling av de krystallinske karboksylatene, farmasöytiske preparater inneholdende disse og deres anvendelse

Info

Publication number
NO302884B1
NO302884B1 NO944644A NO944644A NO302884B1 NO 302884 B1 NO302884 B1 NO 302884B1 NO 944644 A NO944644 A NO 944644A NO 944644 A NO944644 A NO 944644A NO 302884 B1 NO302884 B1 NO 302884B1
Authority
NO
Norway
Prior art keywords
crystalline
carboxylates
trisubstituted
piperidinyl
intermediates
Prior art date
Application number
NO944644A
Other languages
English (en)
Norwegian (no)
Other versions
NO944644D0 (no
NO944644L (no
Inventor
Scott Alan Frank
Douglas Edward Prather
Jeffrey Alan Ward
John Arnold Werner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944644D0 publication Critical patent/NO944644D0/no
Publication of NO944644L publication Critical patent/NO944644L/no
Publication of NO302884B1 publication Critical patent/NO302884B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO944644A 1993-12-08 1994-12-02 Krystallinske 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter, fremgangsmåte for fremstilling av de krystallinske karboksylatene, farmasöytiske preparater inneholdende disse og deres anvendelse NO302884B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (3)

Publication Number Publication Date
NO944644D0 NO944644D0 (no) 1994-12-02
NO944644L NO944644L (no) 1995-06-09
NO302884B1 true NO302884B1 (no) 1998-05-04

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944644A NO302884B1 (no) 1993-12-08 1994-12-02 Krystallinske 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter, fremgangsmåte for fremstilling av de krystallinske karboksylatene, farmasöytiske preparater inneholdende disse og deres anvendelse

Country Status (30)

Country Link
US (1) US5434171A (cg-RX-API-DMAC7.html)
EP (3) EP1607387A3 (cg-RX-API-DMAC7.html)
JP (2) JP3834075B2 (cg-RX-API-DMAC7.html)
KR (1) KR100356239B1 (cg-RX-API-DMAC7.html)
CN (2) CN1057294C (cg-RX-API-DMAC7.html)
AT (1) ATE200279T1 (cg-RX-API-DMAC7.html)
AU (1) AU681198B2 (cg-RX-API-DMAC7.html)
BR (1) BR9404842A (cg-RX-API-DMAC7.html)
CA (1) CA2137221C (cg-RX-API-DMAC7.html)
CO (1) CO4290427A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ290559B6 (cg-RX-API-DMAC7.html)
DE (1) DE69427017T2 (cg-RX-API-DMAC7.html)
DK (1) DK0657428T3 (cg-RX-API-DMAC7.html)
ES (1) ES2155844T3 (cg-RX-API-DMAC7.html)
FI (2) FI106455B (cg-RX-API-DMAC7.html)
GR (1) GR3036136T3 (cg-RX-API-DMAC7.html)
HU (1) HUT71489A (cg-RX-API-DMAC7.html)
IL (1) IL111843A (cg-RX-API-DMAC7.html)
MY (1) MY121543A (cg-RX-API-DMAC7.html)
NO (1) NO302884B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ270039A (cg-RX-API-DMAC7.html)
PE (1) PE41495A1 (cg-RX-API-DMAC7.html)
PL (1) PL181734B1 (cg-RX-API-DMAC7.html)
PT (1) PT657428E (cg-RX-API-DMAC7.html)
RU (1) RU2145958C1 (cg-RX-API-DMAC7.html)
SI (1) SI0657428T1 (cg-RX-API-DMAC7.html)
TW (1) TW290540B (cg-RX-API-DMAC7.html)
UA (1) UA52577C2 (cg-RX-API-DMAC7.html)
YU (2) YU82304A (cg-RX-API-DMAC7.html)
ZA (1) ZA949584B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
ATE446751T1 (de) * 2001-06-05 2009-11-15 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
JP4814488B2 (ja) 2001-10-18 2011-11-16 ネクター セラピューティックス 重合体共役物オピオイドアンタゴニスト
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ,インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN1925875A (zh) 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
CN100579373C (zh) * 2004-06-04 2010-01-13 阿得罗公司 包含鸦片样物质拮抗剂的组合物
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CA2600350C (en) * 2005-03-07 2015-02-10 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US7956220B2 (en) * 2005-07-01 2011-06-07 Jenrin Discovery MAO-B inhibitors useful for treating obesity
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
EP2101773A2 (en) * 2006-11-22 2009-09-23 Progenics Pharmaceuticals, Inc. (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008121352A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
TWI553009B (zh) 2007-03-29 2016-10-11 普吉尼製藥公司 末梢性類鴉片受體拮抗劑及其用途
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009117669A2 (en) 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
WO2011068594A1 (en) 2009-12-04 2011-06-09 Alkermes, Inc. Morphinan derivatives for the treatment of drug overdose
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
WO2016064914A1 (en) 2014-10-20 2016-04-28 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
JP2018534269A (ja) 2015-10-01 2018-11-22 エリージウム セラピューティクス, インコーポレイテッド 過剰摂取および乱用に抵抗性のポリサブユニットオピオイドプロドラッグ
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
WO2018170465A1 (en) 2017-03-17 2018-09-20 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
WO2024090512A1 (ja) * 2022-10-27 2024-05-02 株式会社京都創薬研究所 ナフタレン誘導体の結晶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
NZ242117A (en) * 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
NO944644D0 (no) 1994-12-02
SI0657428T1 (en) 2001-08-31
DE69427017T2 (de) 2001-09-06
RU94042903A (ru) 1996-10-27
KR100356239B1 (ko) 2002-12-26
CA2137221C (en) 2011-02-22
MY121543A (en) 2006-02-28
EP0657428A1 (en) 1995-06-14
AU7917094A (en) 1995-06-15
CA2137221A1 (en) 1995-06-09
FI945703A0 (fi) 1994-12-02
US5434171A (en) 1995-07-18
EP1607387A2 (en) 2005-12-21
ES2155844T3 (es) 2001-06-01
HUT71489A (en) 1995-11-28
FI945703L (fi) 1995-06-09
NZ270039A (en) 1996-08-27
PL181734B1 (pl) 2001-09-28
CN1121387C (zh) 2003-09-17
YU82304A (sh) 2006-03-03
PL306068A1 (en) 1995-06-12
DE69427017D1 (de) 2001-05-10
CO4290427A1 (es) 1996-04-17
DK0657428T3 (da) 2001-05-07
JPH07215937A (ja) 1995-08-15
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
CN1111239A (zh) 1995-11-08
EP1607387A3 (en) 2007-01-03
KR950017957A (ko) 1995-07-22
GR3036136T3 (en) 2001-09-28
EP0984004A3 (en) 2003-10-15
FI20000353L (fi) 2000-02-17
RU2145958C1 (ru) 2000-02-27
HK1013826A1 (en) 1999-09-10
UA52577C2 (uk) 2003-01-15
JP3834075B2 (ja) 2006-10-18
ZA949584B (en) 1996-06-03
PE41495A1 (es) 1995-11-28
JP2006070042A (ja) 2006-03-16
CZ290559B6 (cs) 2002-08-14
CN1223257A (zh) 1999-07-21
BR9404842A (pt) 1995-08-08
EP0657428B1 (en) 2001-04-04
FI106455B (fi) 2001-02-15
YU70294A (sh) 1997-07-31
IL111843A (en) 2000-02-29
PT657428E (pt) 2001-07-31
TW290540B (cg-RX-API-DMAC7.html) 1996-11-11
EP0984004A2 (en) 2000-03-08
AU681198B2 (en) 1997-08-21
IL111843A0 (en) 1995-03-15
CZ299294A3 (en) 1995-10-18
ATE200279T1 (de) 2001-04-15
YU49312B (sh) 2005-06-10
CN1057294C (zh) 2000-10-11
NO944644L (no) 1995-06-09

Similar Documents

Publication Publication Date Title
NO302884B1 (no) Krystallinske 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter, fremgangsmåte for fremstilling av de krystallinske karboksylatene, farmasöytiske preparater inneholdende disse og deres anvendelse
TW218869B (cg-RX-API-DMAC7.html)
IL115790A0 (en) Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof
ZA928643B (en) The resolution of 5-methyltetrahydrofolic acid
EP0328251A3 (en) 2-(2-hydroxy-3-phenoxypropylamino)ethylphenoxyacetamides and processes and intermediates for their preparation
MA23395A1 (fr) Procede de preparation de nouvelles formulations
DK0655454T3 (da) Fremgangsmåde til fremstilling af 2,2-difluorketensilylacetaler og alfa,alfa-difluor-beta-silyloxy-1,3-dioxolan-4-propansyreestere
EP0528034A4 (en) Remedy for asthma
AU696532B2 (en) Amidinophenylalanine derivatives, a process for their preparation, their use and compositions containing these as anticoagulants
FI880868A0 (fi) Välituotteina käyttökelpoisia tetratsoliyhdisteitä
AU628620B2 (en) Foliar glazing agent
DZ1818A1 (fr) Procédé de préparation de compositions orales cotenant des quinolones.
HUT65256A (en) Process for producing 2-mercapto methylene-tetrahydronaphtalene-2-carboxamide derivatives and pharmaceutical preparations containing them
AU1014492A (en) Polyamine phenols as radioprotective agents
IE860045L (en) Composition for disinfecting surfaces by air method
IT8415241V0 (it) Attrezzo agricolo dissodatore od estirpatore o ripuntatore
ITMO930044A0 (it) Utensile per portare alla bocca alimenti.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees